Acute Liver Failure: Science and Practice (RP2003B)

Dallas, TX US
March 30, 2020 to March 31, 2020

Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation.

The Acute Liver Failure Study Group (ALFSG) has been funded by NIDDK since 1997 to collect detailed clinical data on more than 3,500 patients, and will be closing its registry and database permanently in 2019. It is an opportune time to take stock, consider where the field of study of ALF is going, what has been accomplished and to determine future directions of research in this unique syndrome. The audience would include basic scientists that work on liver injury and clinicians (hepatologists, surgeons) who care for these very ill patients.

This two-day program will provide a comprehensive understanding of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to allowing investigators to present work pertaining to pathogenesis and disease mechanisms. The second day of the meeting will be devoted to reviewing aspects of disease management including evaluation, treatment and consideration of prognosis, liver transplantation and liver support devices.​​​​​​

 

This course/program is endorsed by AASLD.  The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Target Audience

THIS ACTIVITY IS INTENDED FOR PROVIDERS IN THE SPECIALTIES OF: 
Anesthesiology
Critical Care Medicine
Gastroenterology and Hepatology
Surgery

Learning Objectives

  • Describe the differences between liver injury from Acetaminophen (APAP) vs. other drugs.
  • Restate the role of cytokines in relation to injury evolution.
  • Explain basic factors that promote liver regeneration.
  • Explain the concept of sterile inflammation.
  • Discuss different mechanisms of liver injury and the role of genomics in susceptibility to acute liver failure.
  • Describe the current state of genome wide association studies. Review current state of identification of single nucleotide polymorphisms (SNPs) for specific diseases/drug injuries
  • Review the elements of the basic and advanced work-ups for ALF patients.
  • Identify natural history, differences in presentation, and how etiology drives prognosis and transplant decisions.
  • Describe the circulatory and neurological physiology of ALF.
  • Explain new understanding regarding hemostasis in ALF, management of kidney injury and hemostasis.
  • Compare present treatment modalities and propose possible future management protocols.
  • Contrast the differences in presentation and outcome of different etiologies.
  • Relate how etiology drives prognosis and transplant decisions.
  • Envision novel approaches to managing ALF in the future.
  • Describe current issues surrounding liver support devices.
     

***PLACEHOLDER: Information about steering committee meeting can go here***

***PLACEHOLDER: Information for young investigators can go here***

Course summary
Available credit: 
  • 12.25 AMA
  • 12.25 Attendance
Course opens: 
10/02/2019
Course expires: 
03/30/2021
Event starts: 
03/30/2020 - 7:00am
Event ends: 
03/31/2020 - 2:00pm
Cost:
$0.00

Monday March 30, 2020

Session 1: Acute Liver Failure: Overview and Mechanisms of Liver Injury

Moderators: Brendan McGuire, MD (UAB) and William M. Lee, MD (UTSW)

TimePresentation TitleSpeaker
8-8:10 amWelcome and IntroductionBrendan McGuire, MD
8:10-8:30 amAcute Liver Failure and ALFSGWilliam M. Lee, MD
8:30-8:50 amPatterns of Liver InjuryNeil Kaplowitz, MD
8:50-9:10 amClinical Phenotypes of ALFRaj Reddy, MD
9:10-9:40 amHistopathology of ALFDavid Kleiner, MD
9:40-10:00 amSIRS and the Role of Infection in ALFAriel Feldstein, MD
10:00-10:15 amDiscussion 

Session 2: Liver Regeneration and Response to Injury

Moderators: Sanjeev Gupta, MD (Albert Einstein) and Michael Schilsky, MD (Yale)

TimePresentation TitleSpeaker
8-8:10 amWelcome and IntroductionBrendan McGuire, MD
10:30-10:55amOverview of Basic Regenerative MechanismsSanjeev Gupta, MD
10:55-11:20 amImmunologic Basis of Liver Injury/ResponseMark McPhail, MD, UK
11:20-11:40 amPlasma Cells and Injury in HBV ALFPatrizia Farci, MD
11:45-12:15 pmBio-markers in ALFMike Schilsky, MD
12:15-12:30 pmDiscussion 

Session 3: Genomics of Liver Injury

Moderators: Raymond Chung, MD (Mass General) and Robert Fontana, MD (U Michigan)

TimePresentation TitleSpeaker
1:15-1:40 pmGenomics OverviewRaymond Chung, MD
1:40-2:05 pmGenomics and Viral Liver InjuryLaurent Casanova, MD,PhD
2:05-2:30 pmGenomics of Drug-Induced Liver InjuryPaola Nicoletti, PhD
2:30-2:45 pmDiscussion 

Session 4: Diagnosis and Evaluation of ALF

Moderators: Jim Hanje, MD (Ohio State) and Dan Ganger, MD (Northwestern University)

TimePresentation TitleSpeaker
3:00-3:25 pmNatural History of ALFKen Simpson, MD
3:25-3:50 pmWorkup of Acute Liver Failure: ChecklistOren Fix, MD
3:50-4:15Case Presentation: New Diagnoses (HLH case)Shannan Tujios, MD
4:15-4:40Causality: Determining Etiology in ALFDaniel Ganger, MD
4:40-5:00 pmDiscussion 

Tuesday March 31, 2020

Session 5: Complications of ALF: Riding Out the Storm

Moderators: Dean Karvellas, MD (Univ. of Alberta) and Jody Olson, MD (Univ. of Kansas)

TimePresentation TitleSpeaker
8:00-8:25 amCritical Care of ALF: OverviewDean Karvellas, MD
8:25-8:50 amHemostasis in ALF: Is There a Coagulopathy?R. Todd Stravitz, MD
8:50-9:10 amFluids, Pressors, Kidney Injury ManagementJody Olson, MD
9:10-9:30 amDiscussion 

Session 6: Prognosis in ALF/Role of Transplantation

Moderator: Ken Simpson, MD (Edinburgh) and David Koch, MD (MUSC)

TimePresentation TitleSpeaker
9:45-10:10 amPrognostic Indices: Determining OutcomesDavid Koch, MD
10:10-10:30 amDesigning Clinical Trials in an Orphan DiseaseValerie Durkalski, PhD
10:30-10:55 amMethacetin Breath Test and Other ToolsRobert Fontana, MD
10:55-11:20 amOutcomes of Transplantation: SRTR and ALFSGJustin Parekh, MD
10:55-11:20 amOutcomes of Transplantation: SRTR and ALFSGJustin Parekh, MD
11:20-11:45 amIs ALF Going Away? An Epidemiologist’s ViewBabak Orandi, MD
11:45-12:00 pmDiscussion 

Session 7: The Future of ALF: Newer Modalities of Liver Support

Moderator: R. Todd Stravitz, MD (MCV) and Scott Nyberg, MD (Mayo Clinic)

TimePresentation TitleSpeaker
1:00-1:20 pmLiver support machines: Current statusScott Nyberg, MD
1:20-1:40 pmStem cell recruitment for liver supportRussell Wesson, MD
1:40-1:50 pmDiscussion 
1:50-2:00 pmFinal wordsWilliam M Lee, MD
UT Southwestern Medical Center - T. Boone Pickens Biomedical Building Auditorium (NG3.112)
6001 Forest Park Rd.
Dallas, TX 75235
United States

Parking: The parking garage is located adjacent to the T. Boone Pickens Biomedical Building. The garage entrance is to the right of the front building entrance. Use elevator to third floor and follow direction signs to the conference room.

Program accessibility: We accommodate people with disabilities. Please call 214-648-2166 for more information. To ensure accommodation, please register as soon as possible.

Travel

Hotel information coming soon!

William Lee, M.D.
UT Southwestern Medical Center
Course Director

Brendan McGuire, M.D.
The University of Alabama at Birmingham
Course Director

R. Todd Stravitz, M.D.
VCU Health
Committee member

Robert J. Fontana, M.D.
University of Michigan Medical School
Committee member

A. James Hanje, M.D.
The Ohio State University Wexner Medical Center
Committee member

Constantine Karvellas, M.D.
University of Alberta
Committee member

Jody Olson, M.D.
The University of Kansas Medical Center
Committee member

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

This course/program is endorsed by AASLD.  The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 12.25 AMA
  • 12.25 Attendance

Accreditation Period

Course opens: 
10/02/2019
Course expires: 
03/30/2021

Price

Cost:
$0.00
Please login or create an account to take this course.

REGISTRATION

Online registration will open soon!

To register:
  1. Create an account in EthosCE, online learning management system, by selecting the "create an account" link at the bottom of the page or "log-in" to your existing account.
  2. Return to this course page, click "Register" tab, and select the designated fee.
  3. In the following "checkout" pages you will verify and process your payment.
  4. After registration is completed, a confirmation will be sent by email.

Refund Policy:

A $25 handling fee will be deducted from cancellation refunds. Refund requests must be received by email at cmeregistrations@utsouthwestern.edu by March 13, 2020. No refunds will be made thereafter.

**Limited onsite registration will be available

***PLACEHOLDER: Information about coupon codes (steering committee members) can go here***